# VG081821AC Tablets for Early to Mid-stage Parkinson's Disease

> **NCT07725562** · PHASE2,PHASE3 · RECRUITING · sponsor: **Zhejiang Vimgreen Pharmaceuticals, Ltd.** · enrollment: 152 (estimated)

## Conditions studied

- Parkinson Disease (PD)

## Interventions

- **DRUG:** VG081821AC
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT07725562
- **Lead sponsor:** Zhejiang Vimgreen Pharmaceuticals, Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-07-17
- **Primary completion:** 2027-10-01
- **Final completion:** 2027-10-31
- **Target enrollment:** 152 (ESTIMATED)
- **Last updated:** 2026-09-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07725562

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07725562, "VG081821AC Tablets for Early to Mid-stage Parkinson's Disease". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07725562. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*